Greek patient healthcare costs: A burden 3-4x EU average

How do Greek healthcare costs affect household stability?

Catastrophic health expenditures are driving approximately 9.5% of the Greek population into financial instability. According to data presented by Professor Charalambos Economou at the 15th Patients' Association of Greece Conference, this figure translates to roughly 404,500 households facing direct medical payments that exceed 40% of their available income.

The breakdown of these devastating costs reveals specific areas of vulnerability:

• Hospital Care: 36% of affected households suffer due to inpatient services.
• Pharmaceuticals: 34% of households are burdened by the inability to afford necessary medications.
• Dental Care: 14% of households struggle with the costs of oral healthcare.

This financial pressure does not just impact liquid savings; it threatens to push families below the poverty line. Approximately 7% of households, or about 302,250 families, are either already below the poverty threshold or are at immediate risk of impoverishment due to these medical costs.

What are the disparities in healthcare spending across income groups?

Healthcare spending in Greece disproportionately impacts the most vulnerable, though even the wealthiest segments face significant costs. The economic burden varies sharply depending on the socio-economic status of the household.

Impact by Income Bracket

The data illustrates a clear divide in how different segments of society manage medical expenses:

In the poorest quintile, more than half of the households are devastated by the cost of medicines. Interestingly, while the wealthiest 20% of the population are less likely to struggle with purchasing drugs, they face an immense burden from hospitalization, with over 65% experiencing catastrophic costs in this area.

Why are pharmaceutical costs so much higher in Greece than in the EU?

Greek patients face pharmaceutical costs that are at least four times higher than those in Germany and nearly triple the European Union average. This disparity is driven by the low level of public funding and the lack of a financial safety net for patients.

According to Antonis Karokis, Corporate Affairs Director at MSD, the private contribution to healthcare in Greece has nearly doubled in recent years, rising from €416 million in 2012 to €810 million in 2024. The funding structure is also inverted compared to the rest of Europe. In Greece, the public sector covers only 36% of pharmaceutical spending, while the pharmaceutical industry and patients cover the remaining 64%. In contrast, public sector coverage in most European countries typically ranges between 65% and 75%.

Patients are often hit twice: first by the mandatory co-payment (either 10% or 25%) and second by the difference between the retail price of the drug and the reimbursement rate set by EOPYY. Unlike many EU nations, Greece lacks a 'ceiling' or maximum cap on out-of-pocket spending. In other countries, once a patient reaches a certain expenditure limit, public coverage rises to 100% for the remainder of the year.

Comparative Pharmaceutical Burden

The impact on a patient with multiple chronic conditions (such as hypertension, diabetes, and high cholesterol) highlights the massive gap in international standards. For a patient with an annual medication cost of €1,980, the out-of-pocket burden in Greece is approximately €396 (3.38% of GDP per capita). By comparison, the costs are significantly lower elsewhere:

• France: 0.15% of GDP per capita.
• United Kingdom: up to 0.30% of GDP per capita.
• Germany: less than 1% of GDP per capita.
• EU Average: 1.26% of GDP per capita.

What are the primary causes of this rising financial burden?

The shift toward individual responsibility and the reduction in public health spending are the primary drivers of the current crisis. Professor Economou notes that institutional and political changes have eroded the stability once provided by social structures, forcing citizens to prioritize basic survival over advocating for their rights.

The legacy of austerity measures during the memorandum years played a critical role. These measures reduced public health spending and introduced ceilings on doctor visits and prescriptions, which ultimately increased the unmet medical needs of the population. This has led to a high degree of 'individualization' of risk, where the state gradually loses its autonomous role in managing health crises, leaving the individual to bear the financial consequences.

How can the Greek healthcare system be reformed?

To mitigate these burdens, experts have proposed several structural changes aimed at decoupling healthcare access from financial contributions and providing more robust protection for low-income citizens.

Professor Economou suggests several key interventions:

• Access Reform: Decoupling the right to healthcare from social security contributions and linking it instead to residency.
• Comprehensive Coverage: Ensuring that the package of covered services includes not just diagnosis and visits, but also outpatient treatments.
• Dental and Long-term Care: Guaranteeing public funding for dental services and long-term care facilities.
• Cost Mitigation: If patient co-payments are necessary, they should be redesigned. This includes exempting low-income individuals from pharmaceutical co-payments, implementing an annual maximum cap on total spending based on income, and replacing percentage-based co-payments with small, fixed amounts.

While some measures like home hospitalization and unified surgical lists have been introduced, their effectiveness remains unproven. The increased burden from afternoon surgeries, the ability of public doctors to engage in private practice, and patient costs for diagnostic centers continue to complicate the landscape.

Frequently asked questions

What is considered a "catastrophic" health expense in Greece?

A health expense is classified as catastrophic when the direct out-of-pocket payments for medical care, such as medicine or hospital stays, exceed 40% of a household's available income. In Greece, this affects approximately 9.5% of the population, or about 404,500 households.

How does Greek pharmaceutical spending compare to the EU average?

Greek patients face pharmaceutical costs that are nearly three times the EU average. While the EU average burden is 1.26% of GDP per capita, Greek patients with chronic conditions can face burdens as high as 3.38% of GDP per capita, largely due to lower public coverage.

Why do Greek patients pay more for medicine than those in France or Germany?

The difference stems from the level of public funding and the absence of a spending cap. In Greece, the public sector covers only 36% of drug costs, whereas in most of Europe, it covers 65-75%. Additionally, Greece lacks a maximum annual limit on out-of-pocket pharmaceutical spending.

Which demographic is most affected by medical costs in Greece?

The poorest 20% of the population is most severely affected, with 57% of these households facing catastrophic costs for medicines. However, the middle class also suffers significantly, with roughly 40% facing catastrophic pharmaceutical expenses and 21% facing high hospitalization costs.

What reforms are being proposed to reduce patient costs?

Experts propose decoupling healthcare access from insurance contributions, guaranteeing public funding for dental and long-term care, and implementing an annual cap on out-of-pocket spending. They also suggest replacing percentage-based co-payments with fixed, low amounts to protect low-income earners.

Key takeaways

• 9.5% of Greek households face catastrophic health expenses exceeding 40% of their income.
• Greek pharmaceutical costs are nearly three times higher than the EU average.
• Public funding for drugs in Greece is only 36%, compared to 65-75% in most of Europe.
• The poorest 20% of Greeks face a 57% catastrophic cost rate for medicines.
• Experts recommend implementing an annual maximum cap on healthcare spending based on income.

Conclusion

The current state of healthcare financing in Greece reveals a systemic vulnerability that disproportionately penalizes the most economically fragile citizens. With pharmaceutical costs nearly triple the EU average and a significant portion of the population facing impoverishment due to medical bills, the need for structural reform is urgent. Moving away from a model of individual responsibility toward one of guaranteed public coverage—including dental and long-term care—is essential. Implementing spending caps and decoupling access from social security contributions could provide the necessary safety net to ensure that health remains a right rather than a financial burden.